Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.

 table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions on using lenalidomide. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.

This guidance looks at the use of lenalidomide for multiple myeloma as third- or further-line treatment. For second-line use, please see NICE’s technology appraisal guidance on lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib.

Is this guidance up to date?

We reviewed the evidence in November 2012. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

May 2019: A simple discount patient access scheme for lenalidomide has replaced the previous complex scheme. This does not affect the cost effectiveness of lenalidomide. Contact HTA_UKandI@celgene.com for details.

Guidance development process

How we develop NICE technology appraisal guidance

This guidance was previously called lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy.

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)